Report of Foreign Issuer (6-k)

FORM 6-K

 

 

SECURITIES AND EXCHANGE COMMISSION


Washington D.C. 20549

 

 

Report of Foreign Issuer

 

 

Pursuant to Rule 13a-16 or 15d-16 of


the Securities Exchange Act of 1934

 

 

 

For period ending September 2015

 

GlaxoSmithKline plc

(Name of registrant)


 

 

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)


 

 

Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F


 

 

Form 20-F x     Form 40-F


 

--


 

Indicate by check mark whether the registrant by furnishing the

information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.


 

 

Yes      No x

--

 

                                                                                                                      GlaxoSmithKline plc

 

Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons

 

In accordance with DTR 3.1.4 R(1)(c) GlaxoSmithKline plc ('GSK') was advised on 14 September 2015 of the following increase in the notional allocation of GSK American Depositary Shares ('ADSs') on 11 September 2015, at a price of $40.26 per ADS, following the revaluation of the cash element of the notional investment held within the GSK 401K plan:

 

 

Connected person	Number of ADSs
Dr K Slaoui (Connected Person of Dr M Slaoui)	9

 

 

V A Whyte

Company Secretary

 

14 September 2015

 

 

 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.


 

 

GlaxoSmithKline plc

(Registrant)


Date: September 14, 2015 

 

 

By: VICTORIA WHYTE

----------------------

 

 

Victoria Whyte

Authorised Signatory for and on

behalf of GlaxoSmithKline plc